Non-overlapping sensitivity to PARPi and PARGi may seem counter-intuitive, as PARP1/2 and PARG work in concert to repair DNA damage; one might expect that both PARPi and PARGi would be toxic towards tumour cells with defects in DNA damage repair [22]. The gene discussed is PARP1; the disease is neoplasm.